Distribution and prognostic value of histopathologic data and immunohistochemical markers in gastrointestinal stromal tumours (GISTs): An analysis of the EORTC phase III trial of treatment of metastatic GISTs with imatinib mesylate.

Sciot, Raf

Distribution and prognostic value of histopathologic data and immunohistochemical markers in gastrointestinal stromal tumours (GISTs): An analysis of the EORTC phase III trial of treatment of metastatic GISTs with imatinib mesylate. [electronic resource] - European journal of cancer (Oxford, England : 1990) Sep 2008 - 1855-60 p. digital

Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial

1879-0852

10.1016/j.ejca.2008.06.003 doi


Antigens, CD34--metabolism
Antineoplastic Agents--administration & dosage
Benzamides
Disease-Free Survival
Dose-Response Relationship, Drug
Exons
Female
Gastrointestinal Stromal Tumors--drug therapy
Humans
Imatinib Mesylate
Immunohistochemistry
Kaplan-Meier Estimate
Male
Mutation--genetics
Piperazines--administration & dosage
Proto-Oncogene Proteins c-kit--genetics
Pyrimidines--administration & dosage
Receptor, Platelet-Derived Growth Factor alpha--genetics